Acceleron Pharma, a clinical stage biotech developing protein therapeutics for cancer and rare diseases, raised $84 million by offering 5.6 million shares at $15, at the high end of the $13 to $15 range. The Cambridge, MA-based company had originally planned to offer 4.7 million shares. Collaboration partner Celgene invested $10 million (0.7 million shares) in a concurrent private placement. Acceleron Pharma, which now commands a market cap of approximately $410 million, will list on the NASDAQ under the symbol XLRN. Citi and Leerink Swann acted as joint bookrunners on the deal.
